In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


deCODE Advances into Clinic with Bayer Drug

Executive Summary

deCODE's recent in-licensing deal with Bayer suggests the biotech's population genetics approach could be set to bear fruit. By in-licensing a compound already shown to be safe, deCODE gets to leapfrog time-consuming drug discovery and early development and move straight into Phase II with its first clinical candidate, saving valuable time and money, and validating its discovery approach to pave the way for additional similar deals. But this inexpensive deal was made for an apparently unwanted compound, and predicated on so-far unsubstantiated claims by deCODE about the link between an unnamed target and heart attack.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts